BRPI1014877A8 - compostos diamida tendo antagonista do receptor muscarínico e atividade agonista do receptor b2 adrenérgico. - Google Patents

compostos diamida tendo antagonista do receptor muscarínico e atividade agonista do receptor b2 adrenérgico.

Info

Publication number: BRPI1014877A8
Authority: BR; Brazil
Prior art keywords: adrenergic; agonist activity; diamide compounds; receptor antagonist; receptor agonist
Prior art date: 2009-04-23

Application number

BRPI1014877A

Other languages

English (en)

Inventor

Hughes Adam

Byun Daniel

L Stangeland Eric

R Jacobsen John

Fleury Melissa

D Wilson Richard

Yen Rose

Chen Yan

Original Assignee

Theravance Respiratory Co Llc

Theravance Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-04-23

Filing date

2010-04-16

Publication date

2018-03-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42272140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1014877(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-04-16 Application filed by Theravance Respiratory Co Llc, Theravance Inc filed Critical Theravance Respiratory Co Llc

2016-04-12 Publication of BRPI1014877A2 publication Critical patent/BRPI1014877A2/pt

2018-03-13 Publication of BRPI1014877A8 publication Critical patent/BRPI1014877A8/pt

2020-11-10 Publication of BRPI1014877B1 publication Critical patent/BRPI1014877B1/pt

2021-05-25 Publication of BRPI1014877B8 publication Critical patent/BRPI1014877B8/pt

Links

229940121948 Muscarinic receptor antagonist Drugs 0.000 title 1
230000001800 adrenalinergic effect Effects 0.000 title 1
150000001470 diamides Chemical class 0.000 title 1
230000000694 effects Effects 0.000 title 1
239000003149 muscarinic antagonist Substances 0.000 title 1
239000000018 receptor agonist Substances 0.000 title 1
229940044601 receptor agonist Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Hydrogenated Pyridines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

BRPI1014877A 2009-04-23 2010-04-16 compostos diamida tendo antagonista do receptor muscarínico e atividade agonista do receptor ß2 adrenérgico, composição farmacêutica e seu uso BRPI1014877B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US17203909P	2009-04-23	2009-04-23
US61/172,039		2009-04-23
PCT/US2010/031356 WO2010123766A1 (en)	2009-04-23	2010-04-16	DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

Publications (4)

Publication Number	Publication Date
BRPI1014877A2 BRPI1014877A2 (pt)	2016-04-12
BRPI1014877A8 true BRPI1014877A8 (pt)	2018-03-13
BRPI1014877B1 BRPI1014877B1 (pt)	2020-11-10
BRPI1014877B8 BRPI1014877B8 (pt)	2021-05-25

Family

ID=42272140

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1014877A BRPI1014877B8 (pt)	2009-04-23	2010-04-16	compostos diamida tendo antagonista do receptor muscarínico e atividade agonista do receptor ß2 adrenérgico, composição farmacêutica e seu uso

Country Status (31)

Country	Link
US (14)	US8138345B2 (pt)
EP (3)	EP3210981B1 (pt)
JP (3)	JP5671006B2 (pt)
KR (1)	KR101769061B1 (pt)
CN (2)	CN102405218B (pt)
AR (1)	AR076412A1 (pt)
AU (1)	AU2010239522B2 (pt)
BR (1)	BRPI1014877B8 (pt)
CA (1)	CA2758505C (pt)
CL (1)	CL2011002637A1 (pt)
CO (1)	CO6440584A2 (pt)
CY (2)	CY1119008T1 (pt)
DK (3)	DK2599778T3 (pt)
ES (3)	ES2635358T3 (pt)
HR (3)	HRP20130468T1 (pt)
HU (2)	HUE042975T2 (pt)
IL (1)	IL215554A (pt)
LT (2)	LT3210981T (pt)
MX (1)	MX2011011156A (pt)
MY (1)	MY158339A (pt)
NZ (1)	NZ595850A (pt)
PL (3)	PL3210981T3 (pt)
PT (3)	PT2599778T (pt)
RU (2)	RU2676686C2 (pt)
SG (1)	SG175330A1 (pt)
SI (3)	SI2421849T1 (pt)
SM (3)	SMT201900168T1 (pt)
TR (1)	TR201903556T4 (pt)
TW (2)	TWI513693B (pt)
WO (1)	WO2010123766A1 (pt)
ZA (1)	ZA201107743B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2635358T3 (es)	2009-04-23	2017-10-03	Theravance Respiratory Company, Llc	Compuestos de diamina que tienen actividad antagonista del receptor muscarínico y agonista del receptor beta2 adrenérgico
EP2386555A1 (en)	2010-05-13	2011-11-16	Almirall, S.A.	New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
ITRM20110083U1 (it)	2010-05-13	2011-11-14	De La Cruz Jose Antonio Freire	Piastra per la costruzione di carrelli per aeroplani
AR083115A1 (es) *	2010-09-30	2013-01-30	Theravance Inc	Sales oxalato cristalinas de un compuesto diamida
BR112013031493B1 (pt)	2011-06-10	2022-04-19	Chiesi Farmaceutici S.P.A	Composto, composição farmacêutica, uso de um composto, combinação de um composto, dispositivo e processo de preparação de um composto
KR20180085068A (ko)	2011-06-10	2018-07-25	키에시 파르마슈티시 엣스. 피. 에이.	무스카린 수용체 길항제 및 베타2 아드레날린 수용체 작용제 효능을 갖는 화합물
EP2592078A1 (en)	2011-11-11	2013-05-15	Almirall, S.A.	New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
SG10201704032RA (en)	2012-12-06	2017-06-29	Chiesi Farm Spa	Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CN104854105B (zh)	2012-12-06	2017-05-17	奇斯药制品公司	具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物
ES2750523T3 (es)	2012-12-18	2020-03-26	Almirall Sa	Derivados de ciclohexil y quinuclidinil carbamato que tienen actividades de agonista beta2 adrenérgicos y antagonistas muscarínicos M3
TWI643853B (zh)	2013-02-27	2018-12-11	阿爾米雷爾有限公司	同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201517906A (zh)	2013-07-25	2015-05-16	Almirall Sa	含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh)	2013-07-25	2018-11-21	阿爾米雷爾有限公司	具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
CN104030933A (zh) *	2014-05-16	2014-09-10	烟台恒迪克能源科技有限公司	一种β-异烷醇基氨基戊酸环己胺的合成方法
TW201617343A (zh)	2014-09-26	2016-05-16	阿爾米雷爾有限公司	具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
TWI703138B (zh)	2015-02-12	2020-09-01	義大利商吉斯藥品公司	具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
WO2016155573A1 (zh) *	2015-03-27	2016-10-06	四川海思科制药有限公司	一种杂环衍生物及其制备方法和在医药上的用途
CN107108502A (zh) *	2015-05-14	2017-08-29	四川海思科制药有限公司	具有β2受体激动及M受体拮抗活性的联苯衍生物及其在医药上的用途
WO2016180348A1 (zh) *	2015-05-14	2016-11-17	四川海思科制药有限公司	具有β2受体激动及M受体拮抗活性的含氮杂螺环衍生物及其在医药上的用途
AR104828A1 (es)	2015-06-01	2017-08-16	Chiesi Farm Spa	COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
WO2017093208A1 (en)	2015-12-03	2017-06-08	Chiesi Farmaceutici S.P.A.	Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
WO2017125060A1 (zh) *	2016-01-22	2017-07-27	四川海思科制药有限公司	一种氮杂环酰胺衍生物及其制备方法和在医药上的用途
WO2018011090A1 (en)	2016-07-13	2018-01-18	Chiesi Farmaceutici S.P.A.	Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
KR102278197B1 (ko)	2016-12-14	2021-07-15	베이징 서우바이 파마슈티컬 컴퍼니 리미티드	4차 암모늄염 구조의 이중기능 화합물
WO2018211530A1 (en)	2017-05-19	2018-11-22	Council Of Scientific & Industrial Research	Substituted methanopyrido [2, 1-a] isoindolonesas machr modulators for treating various associated pathophysiological conditions and process for preparation thereof
US11484531B2 (en)	2018-08-30	2022-11-01	Theravance Biopharma R&D Ip, Llc	Methods for treating chronic obstructive pulmonary disease
US10562930B1 (en) *	2018-08-31	2020-02-18	Praxis Precision Medicines, Inc.	Salts and crystal forms of GABAA positive allosteric modulator
CN117924216A (zh) *	2024-01-12	2024-04-26	王叔和生物医药(武汉)有限公司	一种1-哌啶丙酸的合成方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6362371B1 (en) *	1998-06-08	2002-03-26	Advanced Medicine, Inc.	β2- adrenergic receptor agonists
UA73543C2 (uk)	1999-12-07	2005-08-15	Тераванс, Інк.	Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
ATE299494T1 (de)	1999-12-07	2005-07-15	Theravance Inc	Carbamat-derivate als muscarin-rezeptor antonisten
US6759398B2 (en)	2000-08-05	2004-07-06	Smithkline Beecham Corporation	Anti-inflammatory androstane derivative
CA2417826A1 (en)	2000-08-05	2002-02-14	Glaxo Group Limited	17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
US6750210B2 (en)	2000-08-05	2004-06-15	Smithkline Beecham Corporation	Formulation containing novel anti-inflammatory androstane derivative
US6858596B2 (en)	2000-08-05	2005-02-22	Smithkline Beecham Corporation	Formulation containing anti-inflammatory androstane derivative
UA77656C2 (en)	2001-04-07	2007-01-15	Glaxo Group Ltd	S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
CN1255012C (zh) *	2001-12-04	2006-05-03	东京研发股份有限公司	供电装置
CN101239971B (zh) *	2003-02-14	2011-07-20	施万制药	联苯衍生物
PE20040950A1 (es) *	2003-02-14	2005-01-01	Theravance Inc	DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
ME00557A (en)	2004-01-22	2011-12-20		Sulfonamide derivatives for the treatment of diseases
WO2005080375A1 (en) *	2004-02-13	2005-09-01	Theravance, Inc.	Crystalline form of a biphenyl compound
WO2005092861A1 (en)	2004-03-11	2005-10-06	Pfizer Limited	Quinolinone derivatives pharmaceutical compositions containing them and their use
TWI341836B (en)	2004-03-11	2011-05-11	Theravance Inc	Biphenyl compounds useful as muscarinic receptor antagonists
US7307076B2 (en)	2004-05-13	2007-12-11	Boehringer Ingelheim International Gmbh	Beta agonists for the treatment of respiratory diseases
JP2008510015A (ja) *	2004-08-16	2008-04-03	セラヴァンス，インコーポレーテッド	β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
TWI374883B (en) *	2004-08-16	2012-10-21	Theravance Inc	Crystalline form of a biphenyl compound
JP2008510014A (ja) *	2004-08-16	2008-04-03	セラヴァンス，インコーポレーテッド	β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
CA2641706C (en)	2006-02-08	2014-12-23	Fuji Oil Company, Limited	Edible products with low content of saturated and trans unsaturated fats
GB0602778D0 (en) *	2006-02-10	2006-03-22	Glaxo Group Ltd	Novel compound
TW200811104A (en) *	2006-04-25	2008-03-01	Theravance Inc	Crystalline forms of a dimethylphenyl compound
TW200811105A (en) *	2006-04-25	2008-03-01	Theravance Inc	Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2008096129A1 (en)	2007-02-07	2008-08-14	Argenta Discovery Ltd	Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
WO2010011314A1 (en)	2008-07-25	2010-01-28	Boehringer Ingelheim International Gmbh	Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
ES2635358T3 (es)	2009-04-23	2017-10-03	Theravance Respiratory Company, Llc	Compuestos de diamina que tienen actividad antagonista del receptor muscarínico y agonista del receptor beta2 adrenérgico

2010
- 2010-04-16 ES ES13151470.5T patent/ES2635358T3/es active Active
- 2010-04-16 RU RU2015101032A patent/RU2676686C2/ru active
- 2010-04-16 CN CN201080017581.XA patent/CN102405218B/zh not_active Expired - Fee Related
- 2010-04-16 EP EP17164740.7A patent/EP3210981B1/en active Active
- 2010-04-16 LT LTEP17164740.7T patent/LT3210981T/lt unknown
- 2010-04-16 SI SI201030228T patent/SI2421849T1/sl unknown
- 2010-04-16 SI SI201031498T patent/SI2599778T1/sl unknown
- 2010-04-16 BR BRPI1014877A patent/BRPI1014877B8/pt not_active IP Right Cessation
- 2010-04-16 EP EP10715058A patent/EP2421849B1/en active Active
- 2010-04-16 PT PT131514705T patent/PT2599778T/pt unknown
- 2010-04-16 ES ES17164740T patent/ES2715965T3/es active Active
- 2010-04-16 EP EP13151470.5A patent/EP2599778B1/en active Active
- 2010-04-16 WO PCT/US2010/031356 patent/WO2010123766A1/en not_active Ceased
- 2010-04-16 RU RU2011147374/04A patent/RU2543716C2/ru active
- 2010-04-16 AU AU2010239522A patent/AU2010239522B2/en not_active Ceased
- 2010-04-16 HU HUE17164740A patent/HUE042975T2/hu unknown
- 2010-04-16 DK DK13151470.5T patent/DK2599778T3/en active
- 2010-04-16 HU HUE13151470A patent/HUE035049T2/en unknown
- 2010-04-16 PL PL17164740T patent/PL3210981T3/pl unknown
- 2010-04-16 SM SM20190168T patent/SMT201900168T1/it unknown
- 2010-04-16 CA CA2758505A patent/CA2758505C/en not_active Expired - Fee Related
- 2010-04-16 MX MX2011011156A patent/MX2011011156A/es active IP Right Grant
- 2010-04-16 HR HRP20130468AT patent/HRP20130468T1/hr unknown
- 2010-04-16 SM SM20170305T patent/SMT201700305T1/it unknown
- 2010-04-16 DK DK10715058.3T patent/DK2421849T3/da active
- 2010-04-16 DK DK17164740.7T patent/DK3210981T3/en active
- 2010-04-16 PL PL10715058T patent/PL2421849T3/pl unknown
- 2010-04-16 CN CN201410175377.0A patent/CN103936716B/zh not_active Expired - Fee Related
- 2010-04-16 PL PL13151470T patent/PL2599778T3/pl unknown
- 2010-04-16 ES ES10715058T patent/ES2417339T3/es active Active
- 2010-04-16 SI SI201031866T patent/SI3210981T1/sl unknown
- 2010-04-16 KR KR1020117027797A patent/KR101769061B1/ko not_active Expired - Fee Related
- 2010-04-16 US US12/761,532 patent/US8138345B2/en not_active Expired - Fee Related
- 2010-04-16 NZ NZ595850A patent/NZ595850A/xx not_active IP Right Cessation
- 2010-04-16 LT LTEP13151470.5T patent/LT2599778T/lt unknown
- 2010-04-16 MY MYPI2011004779A patent/MY158339A/en unknown
- 2010-04-16 PT PT107150583T patent/PT2421849E/pt unknown
- 2010-04-16 SG SG2011077765A patent/SG175330A1/en unknown
- 2010-04-16 PT PT17164740T patent/PT3210981T/pt unknown
- 2010-04-16 JP JP2012507275A patent/JP5671006B2/ja not_active Expired - Fee Related
- 2010-04-16 TR TR2019/03556T patent/TR201903556T4/tr unknown
- 2010-04-23 AR ARP100101379A patent/AR076412A1/es active IP Right Grant
- 2010-04-23 TW TW099112926A patent/TWI513693B/zh not_active IP Right Cessation
- 2010-04-23 TW TW104129981A patent/TWI570115B/zh not_active IP Right Cessation
2011
- 2011-10-05 IL IL215554A patent/IL215554A/en active IP Right Grant
- 2011-10-19 CO CO11139777A patent/CO6440584A2/es active IP Right Grant
- 2011-10-21 CL CL2011002637A patent/CL2011002637A1/es unknown
- 2011-10-21 ZA ZA2011/07743A patent/ZA201107743B/en unknown
2012
- 2012-02-08 US US13/369,109 patent/US8551978B2/en not_active Expired - Fee Related
2013
- 2013-06-07 SM SM201300060T patent/SMT201300060B/xx unknown
- 2013-08-12 US US13/964,484 patent/US8816088B2/en not_active Expired - Fee Related
2014
- 2014-07-10 US US14/327,853 patent/US9000173B2/en not_active Expired - Fee Related
- 2014-08-15 JP JP2014165381A patent/JP5965440B2/ja not_active Expired - Fee Related
2015
- 2015-03-04 US US14/638,171 patent/US9394275B2/en not_active Expired - Fee Related
- 2015-05-22 JP JP2015104157A patent/JP2015147807A/ja active Pending
2016
- 2016-06-13 US US15/180,165 patent/US9572802B2/en not_active Expired - Fee Related
- 2016-12-15 US US15/379,673 patent/US9682957B2/en not_active Expired - Fee Related
2017
- 2017-04-26 US US15/497,446 patent/US9771350B2/en not_active Expired - Fee Related
- 2017-05-09 CY CY20171100498T patent/CY1119008T1/el unknown
- 2017-06-26 HR HRP20170960TT patent/HRP20170960T1/hr unknown
- 2017-08-18 US US15/680,323 patent/US9975875B2/en not_active Expired - Fee Related
2018
- 2018-04-23 US US15/959,549 patent/US10138220B1/en not_active Expired - Fee Related
- 2018-10-15 US US16/159,829 patent/US10358433B2/en not_active Expired - Fee Related
2019
- 2019-02-28 CY CY20191100250T patent/CY1121601T1/el unknown
- 2019-03-04 HR HRP20190417TT patent/HRP20190417T1/hr unknown
- 2019-06-07 US US16/434,220 patent/US10590107B2/en not_active Expired - Fee Related
2020
- 2020-01-28 US US16/774,024 patent/US10836744B2/en not_active Expired - Fee Related
- 2020-10-08 US US17/065,689 patent/US20210024493A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US8138345B2 (en)	2012-03-20
BRPI1014877B1 (pt)	2020-11-10
TWI570115B (zh)	2017-02-11
SMT201300060B (it)	2013-07-09
BRPI1014877A2 (pt)	2016-04-12
US10358433B2 (en)	2019-07-23
RU2011147374A (ru)	2013-05-27
US20210024493A1 (en)	2021-01-28
CN102405218A (zh)	2012-04-04
HUE035049T2 (en)	2018-05-02
US10836744B2 (en)	2020-11-17
CN102405218B (zh)	2014-06-04
US20150274697A1 (en)	2015-10-01
MY158339A (en)	2016-09-30
EP2421849B1 (en)	2013-04-03
HRP20190417T1 (hr)	2019-04-19
JP2012524783A (ja)	2012-10-18
AU2010239522B2 (en)	2015-07-02
SI2599778T1 (sl)	2017-08-31
RU2676686C2 (ru)	2019-01-10
PT2421849E (pt)	2013-05-27
EP2599778A1 (en)	2013-06-05
PL2599778T3 (pl)	2018-01-31
JP2015147807A (ja)	2015-08-20
PT3210981T (pt)	2019-04-01
US8551978B2 (en)	2013-10-08
KR20110138292A (ko)	2011-12-26
HK1165799A1 (en)	2012-10-12
IL215554A (en)	2014-08-31
LT3210981T (lt)	2019-04-10
ES2417339T3 (es)	2013-08-07
US20170096412A1 (en)	2017-04-06
TW201546057A (zh)	2015-12-16
JP5671006B2 (ja)	2015-02-18
ZA201107743B (en)	2012-06-27
CA2758505C (en)	2017-03-07
EP3210981A1 (en)	2017-08-30
CN103936716A (zh)	2014-07-23
RU2015101032A3 (pt)	2018-07-30
MX2011011156A (es)	2011-11-04
US20170226082A1 (en)	2017-08-10
TR201903556T4 (tr)	2019-04-22
US20130137665A1 (en)	2013-05-30
EP2599778B1 (en)	2017-04-12
US10590107B2 (en)	2020-03-17
SG175330A1 (en)	2011-11-28
ES2635358T3 (es)	2017-10-03
US9975875B2 (en)	2018-05-22
ES2715965T3 (es)	2019-06-07
DK3210981T3 (en)	2019-04-01
TW201041866A (en)	2010-12-01
RU2015101032A (ru)	2015-06-27
EP3210981B1 (en)	2019-01-02
HUE042975T2 (hu)	2019-07-29
TWI513693B (zh)	2015-12-21
WO2010123766A1 (en)	2010-10-28
BRPI1014877B8 (pt)	2021-05-25
CL2011002637A1 (es)	2012-04-27
US9682957B2 (en)	2017-06-20
PL2421849T3 (pl)	2013-08-30
AR076412A1 (es)	2011-06-08
US20200165223A1 (en)	2020-05-28
KR101769061B1 (ko)	2017-08-17
US20140323733A1 (en)	2014-10-30
JP2014210816A (ja)	2014-11-13
DK2599778T3 (en)	2017-06-26
US9394275B2 (en)	2016-07-19
US20170362200A1 (en)	2017-12-21
PT2599778T (pt)	2017-06-06
LT2599778T (lt)	2017-08-25
NZ595850A (en)	2013-05-31
HRP20170960T1 (hr)	2017-09-22
EP2421849A1 (en)	2012-02-29
CO6440584A2 (es)	2012-05-15
US9771350B2 (en)	2017-09-26
CA2758505A1 (en)	2010-10-28
IL215554A0 (en)	2011-12-29
US9000173B2 (en)	2015-04-07
CY1121601T1 (el)	2020-05-29
US20100273755A1 (en)	2010-10-28
US8816088B2 (en)	2014-08-26
US9572802B2 (en)	2017-02-21
DK2421849T3 (da)	2013-07-01
US20130331364A1 (en)	2013-12-12
CN103936716B (zh)	2016-09-07
US20160361304A1 (en)	2016-12-15
CY1119008T1 (el)	2018-01-10
SI3210981T1 (sl)	2019-05-31
AU2010239522A1 (en)	2011-11-10
SMT201900168T1 (it)	2019-05-10
SI2421849T1 (sl)	2013-07-31
JP5965440B2 (ja)	2016-08-03
US10138220B1 (en)	2018-11-27
PL3210981T3 (pl)	2019-06-28
US20190300504A1 (en)	2019-10-03
HRP20130468T1 (en)	2013-06-30
US20190047984A1 (en)	2019-02-14
SMT201700305T1 (it)	2017-09-07
RU2543716C2 (ru)	2015-03-10

Legal Events

Date	Code	Title	Description
2017-10-17	B25A	Requested transfer of rights approved	Owner name: THERAVANCE RESPIRATORY COMPANY, LLC (US)
2018-03-13	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-07-09	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-07-23	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2020-05-12	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-09-08	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-11-10	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/11/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/04/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2023-02-07	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 13A ANUIDADE.
2023-05-23	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2718 DE 07-02-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI1014877A2 (pt)	2016-04-12	compostos de diamida tendo atividade anatogonista ao receptor muscarínico e atividade agonista do receptor b2 adrenérgico.
LTC2379069I2 (lt)	2022-05-25	S1p receptoriaus agonisto dozavimas
PL3335707T3 (pl)	2024-07-29	Kombinacje antagonisty receptora muskarynowego i agonisty receptora beta-2 adrenergicznego
BRPI1008060A2 (pt)	2015-08-25	Agonistas e antagonistas do receptor s1p5, e métodos de uso do mesmo.
DK2252581T3 (da)	2012-07-16	Kappa-selektiv opioidreceptorantagonist
ATE524460T1 (de)	2011-09-15	Pyridon-gpr119-g-protein-gekoppelte rezeptoragonisten
DK2009992T3 (da)	2012-08-13	Il-8 receptor-antagonister
PT2718280E (pt)	2015-11-25	Compostos possuindo uma atividade antagonista de um recetor muscarínico e agonista de um recetor beta2 adrenérgico
BRPI0815668A2 (pt)	2017-05-23	compostos pirrol tendo atividade biológica antagonista e agonista de receptor de esfingosina-1-fosfato.
EP2350060A4 (en)	2012-07-25	Melanocortin receptor AGONISTS
BRPI0806966A2 (pt)	2014-04-08	Combinação de um antagonista de receptor muscarínico e um agonista beta-2-adrenoceptor
EP2485595A4 (en)	2014-03-12	COMBINATION THERAPY WITH AN ADRENERGIC BETA-3 RECEPTOR AGONIST AND ANTIMIC CARCINU
BRPI0912988A2 (pt)	2019-09-24	compostos bicíclicos tendo atividade no receptor cxcr4.
BRPI0817835A2 (pt)	2015-03-31	Antagonistas cgrp
AP2008004401A0 (en)	2008-04-30	Histamine-3 receptor antagonists
HRP20160950T1 (hr)	2016-10-07	Polimorfi antagonista mglur5 receptora
BR112012002445A2 (pt)	2015-10-13	uso de um agonista do receptor 4 de melanocortina.
EP2271346A4 (en)	2012-02-22	MONOCYCLIC CGRP RECEPTOR ANTAGONISTS
BRPI0918431A2 (pt)	2015-11-24	produto farmacêutico compreendendo um antagonista de receptor muscarínico e um agonista de beta-2-adrenoceptor.
DK2257534T3 (da)	2014-02-03	3-aminoalkyl-1,4-diazepan-2-on-melanocortin-5-receptorantagonister
EP2340025A4 (en)	2012-05-09	CGRP RECEPTOR ANTAGONISTS
EP2341919A4 (en)	2012-05-30	CGRP RECEPTOR ANTAGONISTS
BRPI0908075A2 (pt)	2015-08-25	Antagonísta muscarínicos de pde4-duplos farmacóforos
BRPI0912657A2 (pt)	2016-01-26	produto farmacêutico compreendendo um antagonista de receptor muscarínico e um agonista beta2-adrenorreceptor
EP2331101A4 (en)	2012-08-29	MONOCYCLIC AMID-CGRP RECEPTOR ANTAGONISTS